The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis

Journal of Gastroenterology

Volumn 48, Issue 3, 2013, Pages 405-412

  Takeuchi, Yasuto ^a   Ikeda, Fusao ^a   Moritou, Yuki ^a   Hagihara, Hiroaki ^a   Yasunaka, Tetsuya ^a   Kuwaki, Kenji ^a   Miyake, Yasuhiro ^a   Ohnishi, Hideki ^a   Nakamura, Shinichiro ^a   Shiraha, Hidenori ^a   Takaki, Akinobu ^a   Iwasaki, Yoshiaki ^b   Nouso, Kazuhiro ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; PNPLA3 SNP; Survival

Indexed keywords

ASPARTATE AMINOTRANSFERASE; PHOSPHOLIPASE; SYNAPSIN II; ADIPONUTRIN, HUMAN; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; BODY MASS; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISEASE COURSE; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; JAPANESE; LIPID STORAGE; LIVER CELL CARCINOMA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; VERY ELDERLY; YOUNG ADULT; FOLLOW UP; GENETICS; HEPATITIS B; HEPATITIS C; HEPATITIS E; KAPLAN MEIER METHOD; LIVER TUMOR; PATHOLOGY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATITIS E; HUMANS; KAPLAN-MEIER ESTIMATE; LIPASE; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84878786093     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0647-3     Document Type: Article

References (38)

1. El-Serag HB, Marrero JA, Reddy KR, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134: 1752-63.
2. Kawaguchi T, Taniguchi E, Sata M, et al. The pathogenesis, complications and therapeutic strategy for hepatitis C virusassociated insulin resistance in the era of anti-viral treatment. Rev Recent Clin Trials. 2010;5: 147-57.
3. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51: 1820-32.
4. Fattovich G, Stroffolini T, Donato F, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-50.
5. Hassan MM, Hwang LY, Patt YZ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002;36: 1206-13.
6. Kiyosawa K, Umemura T, Tanaka E, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004;127:S17-26.
7. Taura N, Fukushima N, Taketomi A, et al. The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area. Med Sci Monit. 2010;17:PH7-11.
8. Abe H, Yoshizawa K, Aizawa Y, et al. Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol. 2008;43: 967-74.
9. Marchesini G, Bugianesi E, Rizzetto M, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37: 917-23.
10. James WP. The epidemiology of obesity: the size of the problem. J Intern Med. 2008;263: 336-52.
11. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15: 556-65.
12. Hui JM, Kench JG, George J, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003;38: 420-7.
13. Sugimoto K, Takei Y. Clinicopathological features of non-alcoholic fatty liver disease. Hepatol Res. 2011;41: 911-20.
14. Nouso K, Kobayashi Y, Yamamoto K, et al. Evolution of prognostic factors in hepatocellular carcinoma in Japan. Aliment Pharmacol Ther. 2010;31: 407-14.
15. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127: S5-6.
16. Falleti E, Fabris C, Pirisi M, et al. Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease. Oncology. 2009;77: 304-13.
17. Yang Y, Luo C, Feng R, Bi S. The TNF-alpha, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a metaanalysis. J Cancer Res Clin Oncol. 2010. doi:10.1007/s00432-010-0959-8.
18. Wilson PA, Gardner SD, Crowther DJ, et al. Characterization of the human patatin-like phospholipase family. J Lipid Res. 2006;47: 1940-9.
19. Huang Y, He S, Hobbs HH, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci USA. 2010;107: 7892-7.
20. Kershaw EE, Hamm JK, Flier JS, et al. Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin. Diabetes. 2006;55: 148-57.
21. Romeo S, Kozlitina J, Hobbs HH, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40: 1461-5.
22. Rotman Y, Koh C, Liang TJ, et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology. 2010;52: 894-903.
23. Valenti L, Al-Serri A, Day CP, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51: 1209-17.
24. Tian C, Stokowski RP, Hinds DA, et al. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet. 2010;42: 21-3.
25. Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology. 2007;72(Suppl 1): 2-15.
26. Makuuchi M, Kokudo N, Arii S. Clinical practice guidelines for hepatocellular carcinoma-the Japan Society of Hepatology 2009 update. Hepatol Res. 2010;40(Suppl 1): 2-144.
27. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 5th ed. Tokyo: Kanehara; 2009. p. 19 (in Japanese).
28. Valenti L, Al-Serri A, Day CP, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51: 1209-17.
29. Kollerits B, Coassin S, Kronenberg F, et al. A common variant in the adiponutrin gene influences liver enzyme values. J Med Genet. 2010;47: 116-9.
30. Kotronen A, Johansson LE, Yki-Järvinen H, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia. 2009;52: 1056-60.
31. Kotronen A, Peltonen M, Yki-Järvinen H, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137: 865-72.
32. Kantartzis K, Peter A, Stefan N, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes. 2009;58: 2616-23.
33. Sookoian S, Castaño GO, Pirola CJ, et al. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res. 2009;50: 2111-6.
34. Speliotes EK, Butler JL, Hirschhorn JN, et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology. 2010;52: 904-12.
35. Kawaguchi T, Sumida Y, Matsuda F, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One. 2012;7:e38322.
36. Inoue M, Iwasaki M, Tsugane S, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166: 1871-7.
37. Hara M, Sasaki S. Japan Public Health Center Study Group. Effect of smoking on the association between alcohol consumption and cancer mortality among middle-aged Japanese men: JPHC Study Cohort I. IARC Sci Publ. 2002;156: 165-8.
38. Ishiguro S, Inoue M, Tsugane S, JPHC Study Group, et al. Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. Eur J Cancer Prevent. 2009;18: 26-32.